Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset

ENANTA PHARMACEUTICALS INC

In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.
In subset treated within 3 days of symptom onset, 1.0 log viral load decline seen at Day 5.
Results support further development of EDP-235 for COVID-19.
Updated corporate presentation with additional SPRINT analyses posted on website June 7, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.